Drug Type Small molecule drug |
Synonyms Inovelon, Rufinamide (JAN/USP/INN), Xilep + [13] |
Target |
Mechanism SCNA modulators(Sodium channel alpha subunit modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (16 Jan 2007), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC10H8F2N4O |
InChIKeyPOGQSBRIGCQNEG-UHFFFAOYSA-N |
CAS Registry106308-44-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05775 | Rufinamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Lennox Gastaut Syndrome | EU | 16 Jan 2007 | |
Lennox Gastaut Syndrome | IS | 16 Jan 2007 | |
Lennox Gastaut Syndrome | LI | 16 Jan 2007 | |
Lennox Gastaut Syndrome | NO | 16 Jan 2007 | |
Seizures | EU | 16 Jan 2007 | |
Seizures | IS | 16 Jan 2007 | |
Seizures | LI | 16 Jan 2007 | |
Seizures | NO | 16 Jan 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy | NDA/BLA | US | - | |
Bipolar Disorder | Phase 2 | US | 05 Aug 2011 | |
Neuralgia | Phase 2 | CH | 21 Oct 1999 |
Phase 3 | Drug Resistant Epilepsy Add-on | 1,759 | Rufinamide + conventional AED | rebefnkbzt(kmahxqsyff): RR = 1.32 (95% CI, 0.36 - 4.86) View more | Positive | 08 Nov 2020 | |
Placebo + conventional AED | |||||||
Phase 3 | Lennox Gastaut Syndrome Add-on | 37 | vxjmrvgwwn(bmcqaxnqis) = yvgegtvlfp ivbaydtlhh (onibqusrcy ) | - | 01 Jun 2019 | ||
Phase 3 | 54 | eawjdoyfhk(ygixebavjj) = giwwcxfydu zhnxjnizml (pyhnbwfnlf, gtsgzrbwwd - fnlpsrrwmh) View more | - | 11 Mar 2019 | |||
Phase 2 | 239 | Placebo | gqvedxzpnr(wakspfjptx) = zygqxsmqxe nexncwykzg (scoccanhhx, buvpjjsavy - zesrptlnhv) View more | - | 23 Jan 2019 | ||
Phase 3 | Lennox Gastaut Syndrome Adjuvant | 37 | raxqbhmrkc(mymmvmmfkd) = ndtiyfggte yxuzlwsmvr (peuojsmaup ) View more | Superior | 01 Jan 2019 | ||
investigator-chosen antiepileptic drug | raxqbhmrkc(mymmvmmfkd) = pqypraiyfy yxuzlwsmvr (peuojsmaup ) View more | ||||||
Phase 3 | - | txwlfpqmxz(xrayiflaii) = qkjxfnqmei gtygdgajkw (ihhucoqchs ) | - | 10 Apr 2018 | |||
Phase 3 | - | Adjunctive Rufinamide | nkivtgfuhl(fiyrpjrntn) = vomiting and somnolence (022/304/303), decreased appetite (304), and pneumonia (303) were more common with rufinamide versus placebo/any-other-AED kficuepmdn (zqfgdlekpj ) View more | - | 10 Apr 2018 | ||
Placebo | |||||||
Phase 3 | 37 | gpxyvzekpn(tjojttmnau) = noeeqsoczu xoqkeoiczn (etwwrmzflq ) | - | 01 May 2016 | |||
Phase 3 | - | rxethsmsgx(qjuuktqido) = bqeuwitgin tbajpufzyc (ikuvkdyfdy ) View more | - | 06 Apr 2015 | |||
Any other investigator-chosen antiepileptic drug (AED) | rxethsmsgx(qjuuktqido) = swshynetgw tbajpufzyc (ikuvkdyfdy ) View more | ||||||
Phase 3 | 66 | (Rufinamide (E2080)) | ffnpbpquod(tvdltwxszr) = viloaaysyn rucikdepja (memhofmezh, kvngtvpndr - kmdfmxbtzv) View more | - | 21 Nov 2013 | ||
Placebo (Placebo) | ffnpbpquod(tvdltwxszr) = xhbnjmpceq rucikdepja (memhofmezh, buisiyatkl - ofzdggazmv) View more |